Virtual Heart Care

Introduction: Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor added to aspirin is considered the standard of care for patients

Introduction: Improvements in therapy and prevention have led to declining cardiovascular mortality in the United States, but it is not

Introduction: Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of major adverse cardiovascular events (MACE). Few studies have examined LDL-C

Introduction: Sickle cell trait (SCT) is an independent risk factor for chronic kidney disease (CKD). CKD is a well-established risk

Objective: To evaluate how pharmacological stress agents (PSAs) are used during single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) for

Background: Ticagrelor is a P2Y12 inhibitor with better cardiovascular outcomes than clopidogrel in clinical trials for acute coronary syndromes. However,

Background: The number of patients with cardiac implantable electronic devices (CIEDs) is growing, creating workload for device clinics to manage

Background: Specialty drugs are typically subject to high out-of-pocket (OOP) costs, especially for Medicare Part D patients and commercially insured

Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Influenza infections in patients with underlying CVD

Background: Recent inpatient data abstracted from the National Inpatient Sample and/or National Readmissions Database have shown higher than expected (0.46%)